Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) announced the availability of a significantly lower-cost compounded alternative to Valeant's Calcium Disodium Versenate (edetate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE